Key Developments: Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

95.41EUR
15 Aug 2014
Price Change (% chg)

€-2.28 (-2.33%)
Prev Close
€97.69
Open
€97.78
Day's High
€98.45
Day's Low
€95.03
Volume
2,510,992
Avg. Vol
2,168,393
52-wk High
€114.20
52-wk Low
€89.98

Search Stocks

Latest Key Developments (Source: Significant Developments)

Algeta announces results of voluntary takeover bid made by Bayer's subsidiary
Wednesday, 26 Feb 2014 04:06am EST 

Algeta ASA:Says Bayer has received acceptances for the voluntary takeover offer made through Aviator Acquisition AS for a total of about 42,731,347 shares, representing about 97.28 pct of Algeta's share capital.All regulatory approvals required for completion of the proposed acquisition have been obtained.The transfer of shares to Bayer and the payment of the offer price will take place in the coming days but no later than March 12.Bayer intends to initiate a compulsory acquisition process with the aim of becoming the sole shareholder of Algeta and to file for delisting of the Algeta shares from the Oslo Stock Exchange.Bayer expects to complete the acquisition in Q1 2014.  Full Article

Bayer AG to propose dividend for fiscal year 2013
Tuesday, 25 Feb 2014 07:00pm EST 

Bayer AG:Will propose dividend of 2.10 euro per share for FY 2013.FY 2012 dividend was of 1.90 euro per share.Total dividend payment would amount to 1,737 million euro.  Full Article

Bayer AG extends offer period for voluntary offer to acquire all shares in Algeta ASA
Monday, 24 Feb 2014 02:45am EST 

Algeta ASA:Says Bayer AG is extending the offer period for the voluntary offer to acquire all the shares in Algeta ASA, made through its wholly owned subsidiary Aviator Acquisition AS (hereinafter referred to as Bayer), by two days to Feb. 26 at 09:00 CET.Says all other terms and conditions of the offer remain unchanged.Says Bayer is offering 362 Norwegian crowns in cash per Algeta share.Says that as of Feb. 24 at 07.40 CET, Bayer had received acceptances and pre-acceptances of the offer for about 40,485,490 shares, representing about 92.17 pct of Algeta's share capital.Says the cash offer of 362 Norwegian crowns for each Algeta share represents an equity value of 17.6 bln Norwegian crowns (2.1 bln euros) and an enterprise value of 16.2 bln Norwegian crowns (1.9 bln euros).  Full Article

Bayer AG's Bayer HealthCare initiates phase III trial of Stivarga (regorafenib) tablets in patients with colorectal cancer after resection of liver metastases
Thursday, 20 Feb 2014 02:30am EST 

Bayer HealthCare:Begun to enroll patients in the COAST trial studying Stivarga (regorafenib) tablets in colorectal cancer (CRC) patients with resected liver metastases.Says randomized, double-blind, placebo-controlled Phase III trial is designed to determine the effects of Stivarga as adjuvant treatment following surgical removal of liver metastases.Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG.  Full Article

Cellectis SA's subsidiary signed new agreements with Bayer CropScience, subsidiary of Bayer AG
Thursday, 30 Jan 2014 01:00am EST 

Cellectis SA:Says subsidiary of Cellectis SA has signed two new agreements with Bayer CropScience, a subsidiary of Bayer AG.Says the agreements extend the companies existing partnership to introduce targeted modifications to selected plant genes and genomes.Says the financial terms of these agreements are not disclosed.  Full Article

Bayer AG issues 2 billion euros Eurobond in three tranches
Friday, 24 Jan 2014 06:44am EST 

Bayer AG:Says it has issued a Eurobond with three tranches in Jan.Says Tranche A (ISIN XS1023268060), which matures in Jan. 2016 has a nominal value of 500 million euros and was sold at an issue price of 100 percent with a floating rate coupon is determined by the 3-month-Euribor plus a margin of 22 basis points.Says Tranche B (ISIN: (XS1023268490) matures in Jan. 2018 and has a nominal value of 750 million euros and was sold at an issue price of 99.674 percent and pays a fixed rate coupon of 1.125 percent.Says Tranche C (ISIN: XS1023268573) matures in Jan. 2021 and has a nominal value of 750 million euros and was sold at an issue price of 98.914 percent and pays a fixed rate coupon of 1.875 percent.  Full Article

Bayer commences voluntary cash offer to acquire the entire issued share capital of Algeta
Monday, 20 Jan 2014 02:40am EST 

Algeta ASA:Says that Aviator Acquisition AS, a wholly-owned subsidiary of Bayer Nordic SE, has commenced the voluntary cash offer to acquire the entire issued share capital of Algeta for 362 Norwegian crown per share.Says the Offer period starts on Jan. 20 and expires at CET on Feb. 24.  Full Article

Alliance Pharma Plc's subsidiary acquires rights to thyroid product Irenat from subsidiaries of Bayer AG
Tuesday, 14 Jan 2014 02:00am EST 

Alliance Pharma Plc:Says its wholly owned subsidiary Alliance Pharmaceuticals Limited has acquired the rights to the thyroid product Irenat from subsidiaries of Bayer AG.  Full Article

Algeta ASA's Board unanimously recommends voluntary cash offer from Bayer AG to acquire the entire issued share capital of Algeta
Thursday, 19 Dec 2013 02:07am EST 

Algeta ASA:Says an agreement with the Bayer AG (Bayer) whereby Bayer, through Aviator Acquisition AS, a wholly-owned subsidiary of Bayer Nordic SE, will launch a voluntary cash offer (the Offer) to acquire the entire issued share capital of Algeta for 362 norwegian krone per share in cash.Says the offer values the total share capital of Algeta at about 17.6 bln norwegian krone ($2.9 bln) on a fully diluted basis.Says the board of directors of Algeta has unanimously decided to recommend that its shareholders accept the Offer.Says under the terms of the offer, Aviator Acquisition AS will make a voluntary offer to acquire the entire issued share capital of Algeta for 362 per share norwegian krone in cash.Says Bayer will finance the transaction with available cash and new debt.Says Bayer expects to close the transaction during the Q1 2014.Says Goldman Sachs International is acting as exclusive financial advisor to Algeta. Skadden, Arps, Slate, Meagher & Flom LLP and Wikborg, Rein & Co. DA are acting as legal advisors to Algeta.Says Centerview Partners provided an additional fairness opinion in support of the Board of Directors' recommendation of the Offer.  Full Article

Algeta ASA confirms that it is in receipt of preliminary acquisition proposal from Bayer AG
Tuesday, 26 Nov 2013 01:25am EST 

Algeta ASA:Confirms that it is in receipt of a preliminary acquisition proposal from Bayer AG.Says preliminary acquisition proposal is Norwegian Krone 336 per Algeta share.Says no certainty that this preliminary acquisition proposal will lead to a transaction or as to the terms of any such transaction.  Full Article

Photo

Private equity eyes $13 billion Bayer plastics business: sources

FRANKFURT/LONDON - Private equity firms are circling Bayer's 10 billion-euro ($12.7 billion) plastics business, hoping to divert the German drugmaker from its plan to list the division, two people familiar with the matter said on Wednesday.

Search Stocks